Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

The full results of a phase 3 clinical trial showed that patients with moderate-to-severe active systemic lupus erythematosus (SLE) who received standard treatment achieved greater reductions in ...

We provide access to a range of journals, databases and other evidence-based resources for health and social care staff in England. You'll need an NHS OpenAthens account to access most of these ...